COR Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

308.470

Open

301.230

VWAP

304.32

Vol

1.89M

Mkt Cap

59.24B

Low

300.000

Amount

574.71M

EV/EBITDA(TTM)

12.77

Total Shares

194.56M

68.48B

EV/OCF(TTM)

30.09

P/S(TTM)

0.18

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

Events Timeline

(ET)

2026-06-15

16:30:00

Cencora HR Executive Announces Retirement

2026-05-27 (ET)

2026-05-27

07:10:00

Still Sees Adjusted Operating Income Growth of 7%-10%

2026-05-27

07:00:00

Cencora Maintains FY26 Adjusted EPS View at $17.70-$17.90

2026-05-27

07:00:00

Cencora Appoints Eva Boratto as EVP and CFO

2026-05-21 (ET)

2026-05-21

16:40:00

Company Updates FY26 Guidance, Plans $1B Stock Buyback

News

9.5

07-01Newsfilter

Cencora to Release Q3 Fiscal 2026 Results on August 5, 2026

6.5

06-24Yahoo Finance

Amgen vs Iovance: Investment Comparison

2.0

06-19NASDAQ.COM

Cardinal Health Continues Growth with Stock Price Surge

1.0

06-17Globenewswire

Successful Virtual Investor Conference Held

1.0

06-16Globenewswire

Agenda Released for Energy & Precious Metals Investor Summit

1.0

06-11Globenewswire

Energy & Precious Metals Investor Summit Scheduled for June 16

9 Analyst Rating

Wall Street analysts forecast COR stock price to rise

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

400.00

Averages

415.38

High

440.00

Current: 0.000

Low

400.00

Averages

415.38

High

440.00

BofA

Allen Lutz

Neutral

maintain

$280 -> $285

AI Analysis

2026-06-24

Reason

BofA

Allen Lutz

Price Target

$280 -> $285

AI Analysis

2026-06-24

maintain

Neutral

Reason

BofA analyst Allen Lutz raised the firm's price target on Cencora (COR) to $285 from $280 and keeps a Neutral rating on the shares. At the firm's Healthcare conference last month, McKesson (MCK) and Cencora made comments that they are, or could, contemplate biosimilar co-manufacturing in the future, notes the analyst, who believes management commentary indicates a clear willingness to explore this opportunity over time. The firm slightly raised Cencora's target multiple to reflect some modest optionality around Eylea, somewhat offset by its customer Cigna's (CI) growing biosimilar ambitions, the analyst noted.

Wells Fargo

Stephen Baxter

Overweight

downgrade

$429 -> $331

2026-05-11

Reason

Wells Fargo

Stephen Baxter

Price Target

$429 -> $331

2026-05-11

downgrade

Overweight

Reason

Wells Fargo analyst Stephen Baxter lowered the firm's price target on Cencora (COR) to $331 from $429 and keeps an Overweight rating on the shares. The firm says that the magnitude of U.S. HC earnings growth deceleration was a disappointment. That said, Wells sees "core" growth generally in-line with peers Cardinal Health (CAH) / McKesson (MCK). If "core" growth is sustained in this general area, the firm would expect the price to earnings gap to close some.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for COR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 14.81, compared to its 5-year average forward P/E of 15.15. For a more detailed relative valuation and DCF analysis to assess Cencora Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

15.15

Current PE

14.81

Overvalued PE

17.55

Undervalued PE

12.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.36

Current EV/EBITDA

9.36

Overvalued EV/EBITDA

13.63

Undervalued EV/EBITDA

9.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.14

Current PS

0.16

Overvalued PS

0.17

Undervalued PS

0.12

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

top high conviction u.s. stocks

Intellectia · 18 candidates

Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong BuyPe Ttm: <= 25List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC, NDX, DJI, RUTFree Cash Flow Ttm: >= 0

Ticker

Name

Market Cap$

SCHW

Charles Schwab Corp

158.44B

UBER

Uber Technologies Inc

140.15B

NEM

Newmont Corporation

107.00B

RCL

Royal Caribbean Cruises Ltd

78.95B

Cigna Group

78.83B

Barrick Mining Corp

67.35B

top stocks in health sector

Intellectia · 38 candidates

Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

866.87B

ABBV

AbbVie Inc

364.65B

AZN

AstraZeneca PLC

293.00B

MRK

Merck & Co Inc

282.35B

UNH

UnitedHealth Group Inc

254.55B

AMGN

Amgen Inc

188.63B

run based on daily

Intellectia · 80 candidates

Ticker

Name

Market Cap$

SPOT

Spotify Technology SA

103.40B

COR

Cencora Inc

68.24B

AFL

Aflac Inc

56.90B

MSCI

MSCI Inc

44.25B

ONC

BeOne Medicines AG

40.49B

Consolidated Edison Inc

37.48B

Whales Holding COR

TimesSquare Capital Management, LLC

T. Rowe Price Group, Inc.

Livförsäkringsbolaget Skandia, ömsesidigt

SEB Investment Management AS

Clark Capital Management Group Inc

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cencora Inc (COR) stock price today?

The current price of COR is 304.48 USD — it has increased 1.99

What is Cencora Inc (COR)'s business?

What is the price predicton of COR Stock?

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is415.38 USD with a low forecast of 400.00 USD and a high forecast of 440.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.